Acuta Capital Partners LLC Grows Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Acuta Capital Partners LLC lifted its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 9.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,976 shares of the biotechnology company's stock after buying an additional 1,976 shares during the period. Ascendis Pharma A/S makes up 3.2% of Acuta Capital Partners LLC's portfolio, making the stock its 12th biggest position. Acuta Capital Partners LLC's holdings in Ascendis Pharma A/S were worth $3,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the stock. Virtus ETF Advisers LLC boosted its stake in shares of Ascendis Pharma A/S by 3.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock valued at $368,000 after purchasing an additional 100 shares during the period. Legato Capital Management LLC increased its position in shares of Ascendis Pharma A/S by 7.5% during the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after acquiring an additional 134 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S in the third quarter valued at about $30,000. Finally, GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently commented on ASND. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price for the company. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Royal Bank of Canada began coverage on Ascendis Pharma A/S in a research note on Wednesday, April 16th. They issued an "outperform" rating and a $205.00 price target for the company. Finally, Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Trading Down 1.7 %

NASDAQ ASND opened at $167.47 on Friday. The company has a 50-day moving average price of $154.90 and a two-hundred day moving average price of $139.95. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $173.00. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of -23.59 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. As a group, equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.